Nauffal, Mary
https://orcid.org/0000-0002-4957-6954
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Citations 1
Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐versus‐host disease — a real‐world outcomes analysis
Abedin, Sameem , Rashid, Nahid , Nauffal, Mary , Kharfan‐Dabaja, Mohamed A. , Palmer, Jeanne , Larson, Samantha, Holtan, Shernan G. , DeFilipp, Zachariah , Dholaria, Bhagirathbhai , Pidala, Joseph, Khimani, Farhad , Butler, Candace, Alhaj Moustafa, Muhamad, Kharfan-Dabaja, Mohamed A , Hogan, William, Hamadani, Mehdi , Dholaria, Bhagirathbhai R , Holtan, Shernan , Abedin, Sameem , Schroeder, Mark A. , Romee, Rizwan , Moustafa, Muhamad Alhaj , Hogan, William J. , Hefazi, Mehrdad , Jayani, Reena , Grunwald, Michael R. , Hamadani, Mehdi
British Journal of Haematology | July 13, 2021 | Volume: 195 | Issue: 3 | Pages: 429-432
SummaryRuxolitinib for steroid‐refractory acute graft‐versus‐host disease (SR‐aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR‐aGVHD studies.